PDCD1 and neoplasm: CDA targeting in Panc02 cancer cells resulted in decreased tumor growth and weight and complete regression following anti-PD-1 treatment compared to resistant control (sgNT) tumors (Fig. 2a and Extended Data Fig. 3c–e).